2,4,6-tris(3-bromophenyl)-1,3,5-triazine | CAS:890148-78-4

We serve 2,4,6-tris(3-bromophenyl)-1,3,5-triazine CAS:890148-78-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,4,6-tris(3-bromophenyl)-1,3,5-triazine

Chemical Name:2,4,6-tris(3-bromophenyl)-1,3,5-triazine
CAS.NO:890148-78-4
Synonyms:2,4,6-tris(3-bromophenyl)-s-triazine
1,3,5-tris(3-bromophenyl)triazine
2,4,6-tris(3-bromophenyl)triazine
Molecular Formula:C21H12Br3N3
Molecular Weight:546.05200
 
Specification:
Appearance:White powder
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 2,4,6-tris(3-bromophenyl)-1,3,5-triazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4,6-tris(3-bromophenyl)triazine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4,6-tris(3-bromophenyl)-1,3,5-triazine Use and application,2,4,6-tris(3-bromophenyl)-s-triazine technical grade,usp/ep/jp grade.


Related News: But several border points remain open, and many medical workers fear that Hong Kong’s well-regarded health care system will be overwhelmed.L-Norleucine manufacturer Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.Tetraethyl orthosilicate supplier Three more patients have been confirmed infected with coronavirus in South Korea, bringing the country’s total to 15, the South Korean Centers for Disease Control and Prevention (KCDC) announced in a press release.Bromotris(dimethylamino)phosphonium hexafluorophosphate vendor European companies are the main suppliers of specialty APIs, but due to environmental and cost pressures, APIs have begun to shift to the Asian market.“We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”